Boston Scientific

Source: online.wsj.com --- 4 days ago
Boston Scientific's profit fell 15% amid slumping sales of drug-coated stents. The medical-device maker issued a rosy third-quarter outlook, but shares were down after hours. ...

Source: www.boston.com --- 3 days ago
Shares in Boston Scientific Corp. were down nearly 12 percent in late-morning trading after the Natick medical device maker reported a profit drop in quarterly results released yesterday afternoon. On the New York Stock Exchange this morning, company shares were trading at $12.17, down $1.63. Yesterday Boston Scientific said that second-quarter profit dropped 15 percent as rivals cut into sales of its heart stents and defibrillators. Please click here to read an item on Boston Scientific that appeared in the "Earnings roundup" section of today's Globe. Please click here to read the second-quarter press release that Boston Scientific issued yesterday. (By Chris Reidy, Globe staff) ...

Source: seekingalpha.com --- 3 days ago
Boston Scientific Corporation (BSX) Q2 FY08 Earnings Call Complete Story » ...

Source: www.moreover.com --- 1 hour ago
Endovascular Today Jul 26 2008 3:07AM GMT ...

Source: seekingalpha.com --- 12 days ago
Tate Dwinnell submits: The following post is provided exclusively to readers by the good folks at TheCorrectCall.com .   I agree that medical and drug stocks are showing some resiliency... some even showing very bullish action, but being a technical trader myself, I personally would hold off on Boston Scientific (BSX) until it gets back above key resistance levels of the 50 and 200 day moving averages.  Perhaps its upcoming earnings report will be just the catalyst to do so.  ::::::::::::::::::::::: Complete Story » ...

Source: www.newsisfree.com --- 3 days ago
[in Smartmoney: Breaking News ] ...

Source: bsx.bloggingstocks.com --- 6 days ago
Filed under: Bad news , Launches , Industry , Competitive strategy , Abbott Laboratories (ABT) , Boston Scientific (BSX) Abbott Laboratories (NYSE: ABT ) got approval for its new drug-coated stent. The products are used to open clogged arteries, often in the place of by-pass surgery. The field has been dominated by deeply troubled medical device company Boston Scientific (NYSE: BSX ). It looks that the weakened company is in for much more pain. According to The Wall Street Journal , ABT "received regulatory approval for its Xience V drug-coated stent, which is expected to be the top seller in the roughly $2 billion U.S. market because it appears to be more effective than rival devices." Boston Scientific will sell the new Abbott product, but with 40% of the revenue going to its rival, it is hard to see how that is a good deal. BSX has been beaten by competition at almost every turn. It took on tremendous debt when it bought medical device company Guidant. It faced trouble when some Guidant products hit quality control issues. Boston Scientific stents came under criticism a year ago, when medical research questioned how effective they were. BSX traded at almost $45 in 2004. It is now at about $12. With new competition and a bad balance sheet, that is not likely to change much. Douglas A. McIntyre is an editor at 247wallst.com.   Read  |  Permalink  |  Email this  |  Linking Blogs  |  Comments ...

Source: www.sepiamutiny.com --- 4 days ago
Kind of old news but is interesting enough for posting - During Baltimore's visit, the staff showed him his own review paper on RNA which he had submitted to the journal Immunity and which TnQ had processed and edited from its facilities. "[I was] impressed by the Scientific knowledge of the staff," he told a room of international reporters this morning at the inaugural breakfast of the association's 2008 meeting. ...

Source: www.twincities.com --- 4 days ago
NATICK, Mass. — Medical device maker Boston Scientific Corp., which employs about 6,000 people in two Twin Cities divisions, today said its second-quarter profit declined, hurt by acquisition, restructuring and other charges, as revenue inched lower. ...

Source: www.streetinsider.com --- 4 days ago
Visit StreetInsider.com at http://www.streetinsider.com/Guidance/Boston+Scientific+%28BSX%29+Tops+Q2+View%3B+Guides+Q3+Above+the+Street/3835407.html for the full story. ...

Source: www.streetinsider.com --- 12 hours ago
Visit StreetInsider.com at http://www.streetinsider.com/New+Coverage/Piper+Jaffray+Initiates+Boston+Scientific+%28BSX%29+with+a+Buy+/3848234.html for the full story. ...

Source: www.streetinsider.com --- 4 days ago
Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/%2ARevised%2A+Analyst+Reports+for+Boston+Scientific+Corporation%2C+UnitedHealth+Group+Incorporated%2C+Loews+Corporation%2C+and+Timken+Company/3834276.html for the full story. ...

Source: selfinvestors.com --- 8 days ago
The following post is provided exclusively to readers of SelfInvestors.com by the good folks at TheCorrectCall.com.  I agree that medical and drug stocks are showing some resiliency.. some even showing very bullish action, but being a technical trader myself I personally would hold off on Boston Scientific until it gets back above key resistance [...] ...

Source: mcsmith.blogs.com --- 10 days ago
Medtronic v. Boston Scientific Corp., 2:06cv078-TJW (E.D. Tex. July 11, 2008) Judge: T. John Ward Holding: Defendant's Motion for Judgment As A Matter of Law Par. 5 GRANTED Two days after Boston Scientific lost all of its post-trial motions before... ...

Source: www.web2.cl --- 3 days ago
CHICAGO (Reuters) - El fabricante de instrumental médico Boston Scientific Corp dijo el lunes que sus ganancias del segundo trimestre cayeron un 15 por ciento, por una baja de las ventas de sus stent liberadores de medicina y cargos por adquisiciones, desinversiones e iniciativas de reestructuració ...

Source: mnpr.blogspot.com --- 8 days ago
Boston Scientific - Sr. Public Relations Project Manager ...

Source: www.theoptionsinsiders.com.com --- 4 days ago
The top ten most active equity options and strikes for 7/21/2008. Includes GM Ord (GM), Wachovia (WB), Amgen (AMGN), Bank of America (BAC), Merrill Lynch (MER), Boston Scientific (BSX), and Vulcan Materials (VMC). ...

Source: twincities.bizjournals.com --- 4 days ago
Charges for restructuring and divestments hurt Boston Scientific Corp.’s quarterly earnings, though the med-tech company saw an uptick in cardiac-product sales. (BSX) ...

Source: www.stockworld.de --- 4 days ago
JP Tokyo Stock Exchange geschlossen US Apple Ergebnis 3. Quartal US Bank of America Ergebnis 2. Quartal US Boston Scientific Ergebnis 2. Quartal US Hasbro Quartalszahlen. ...